Aug 27, 2010 by Brian Orelli, PhDIgnoring This Could Put Your Investment at RiskA look at drugmakers' inventories.
Aug 27, 2010 by Brian Orelli, PhDInsiders Are Buying Exelixis. Should You?Maybe, but not because they're buying.
Aug 27, 2010 by Brian Orelli, PhDDown 35%! This Just Shouldn't HappenSomeone's to blame and it isn't ImmunoGen.
Aug 27, 2010 by Brian Orelli, PhDA Recall a Week, That's All We AskFor Johnson & Johnson, apparently that's too much.
Aug 26, 2010 by Brian Orelli, PhDDrug Prices Up, but Don't Read Too Much Into ItIt can't last forever, you know.
Aug 25, 2010 by Brian Orelli, PhDShares Soar! That'll Help Investors Sleep Better Tonight.Somaxon finds a marketing partner for its insomnia drug.
Aug 24, 2010 by Brian Orelli, PhDPfizer's Wonder Drug That Wasn'tThree hits. Three misses. Thank goodness this isn't baseball.
Aug 24, 2010 by Brian Orelli, PhDDisaster in Medical-Device LandIndustry bellwether Medtronic is forecasting a nasty storm.
Aug 20, 2010 by Brian Orelli, PhDDepression Is Painful. Advisory Panels More So.Eli Lilly's Cymbalta has a rough time in from of the panel of experts.
Aug 20, 2010 by Brian Orelli, PhDThis Billionaire Likes Biotech. Should You?It depends on how much you trust management.
Aug 19, 2010 by Brian Orelli, PhDHigh Risk, High Reward. At Least It Was Cheap!Biogen licenses a drug to treat ALS.
Aug 19, 2010 by Brian Orelli, PhDThe Mice Can Walk!Too bad there's no market for curing their paralysis.
Aug 18, 2010 by Brian Orelli, PhDMore Pain Ahead for Eli Lilly?An advisory panel meeting tomorrow could further the company's slide.
Aug 17, 2010 by Brian Orelli, PhDMake a Financing Deal and Lose 10%. Nice.Two cash raises in less than a week don't inspire confidence.
Aug 17, 2010 by Brian Orelli, PhDForget About This Drug Saving the CompanyLilly's Alzheimer's drug fails hard.
